

TABLE OF THE CONTENTS

Topic	Page No.
ABSTRACT	i
PREFACE.....	v
Acknowledgement.....	vi
TABLE OF THE CONTENTS.....	vii
LIST OF TABLES.....	xiii
LIST OF FIGURES.....	xv
LIST OF APPENDIXES.....	xxiv
Chapter I: General Introduction.....	1–16
Introduction.....	1
I.1. Schiff base ligand and its importance.....	3
I.2. Bioactive compound and its importance.....	5
I.3. Synthesis of bioactive compounds by transition metal complex.....	7
I.4. Transition metal-free synthesis of bioactive compound.....	9
I.5. Scope and objectives of the present study.....	11
References.....	13–16
Chapter II: Catalytic Oxidative Coupling of o-Phenylenediamine, In-vitro Antibacterial and Antitumor Activities of a Gold(III)-Bipyridine Complex.....	17–45
II.1. Introduction.....	17
II.2. Experimental section.....	18
II.2.1. Preparation of the complex.....	18
II.2.1.1. Chemicals, solvents and starting materials.....	18
II.2.1.2. General procedure for synthesis of complex 1.....	19
II.2.2. Physical measurements.....	19
II.2.3. Crystal structure determination and refinement.....	19
II.2.4. Hirshfeld analysis.....	20
II.2.5. Oxidation of o-phenylenediamine by complex 1.....	20
II.2.6. Antibacterial study of complex 1.....	21
II.2.6.1. Minimum inhibitory concentration of complex 1 by resazurin assay.....	21
II.2.6.1.1. Preparation of the resazurin.....	21

II.2.6.1.2. Resazurin microtitre assay (RMA).....	21
II.2.7. Protocol for biological activities.....	22
II.2.7.1. Cell culture.....	22
II.2.7.2. Cell viability assay.....	22
II.2.8. Acridine orange (AO)/ethidium bromide (EB) and Hoechst 33258 staining.....	22
II.2.9. Assessment of mitochondrial membrane potential ($\Delta\Psi_m$) (JC1 staining).....	23
II.2.10. Computational details.....	23
II.3. Results and discussion.....	24
II.3.1. Synthesis and structural composition of complex 1.....	24
II.3.2. Infrared spectral analysis.....	24
II.3.3. Electronic spectral analysis.....	25
II.3.4. Crystal structure analysis of complex 1.....	25
II.3.5. Analysis of theoretically optimized structure of Complex 1.....	28
II.3.6. MEP and Hishfeld surface analysis.....	30
II.3.7. Catalytic oxidation of OPD.....	32
II.3.8. Mechanistic pathway.....	35
II.3.9. In vitro antibacterial activity of complex 1.....	36
II.3.9.1. Minimum inhibitory concentration by RMA.....	37
II.3.9.10. In vitro cytotoxicity assays for complex 1 against human lung cancer cell line (A549).....	38
II.3.10.1. Morphological observation of apoptosis.....	39
II.3.11. Loss of mitochondrial membrane potential ($\Delta\Psi_m$).....	40
II.4. Conclusions.....	41
References.....	42–45
Chapter III: Bio-mimics of phenazine oxidase activity of a cobalt(III) complex: spectroscopic, structural and computational studies.....	46–81
III.1. Introduction.....	46
III.2. Experimental section.....	47
III.2.1. Preparation of the complex.....	47
III.2.1.1. Chemicals, solvents and starting materials.....	47
III.2.1.2. Synthesis of $[\text{Co}(\text{dpa})(\text{dpa-H}^+)(\text{N}_3)_2]\text{Cl}_2$ (Complex 2).....	47
III.2.2. Physical measurements.....	48
III.2.3. Crystal structure determination and refinement.....	48

III.2.4. Hirshfeld surface analysis.....	48
III.2.5. Oxidation of o-phenylenediamine (OPD) by complex 2.....	49
III.2.6. Computational details.....	49
III.3. Results and discussion.....	50
III.3.1. Synthesis of the complex 2.....	50
III.3.2. Infrared Spectral analysis Complex 2.....	50
III.3.3. Electronic spectrum analysis.....	51
III.3.4. ESI–MS spectrum analysis.....	52
III.3.5. NMR spectral analysis of complex 2.....	53
III.3.6. Description of crystal structure and supramolecular frameworks of complex 2.....	54
III.3.7. Hirshfeld surface analysis of complex 2.....	58
III.3.8. Crystal engineering perspective of $\text{DAPH}^+\text{Cl}^- \cdot 3\text{H}_2\text{O}$ (compound 1).....	59
III.3.9. Hirshfeld surface analysis of $\text{DAPH}^+\text{Cl}^- \cdot 3\text{H}_2\text{O}$ (compound 1).....	62
III.3.10. Computational studies.....	63
III.3.11. Bio-mimics of phenazine oxidase activity.....	65
III.3.11.1. Spectrophotometry and mass spectrometry studies.....	65
III.3.11.2. Electrochemical analysis.....	71
III.3.11.3. Computational calculations.....	73
III.3.12. Mechanistic pathway.....	75
III.4. Conclusion.....	75
References.....	77–81
Chapter IV: A hydrated 2,3-diaminophenazinium chloride as a promising building block against SARS-CoV-2.....	82–122
IV.1. Introduction.....	82
IV.2. Experimental section.....	84
IV.2.1. Preparation of the 2,3-diaminophenazinium chloride (DAPH^+Cl^-).....	84
IV.2.1.1. Chemicals, solvents and starting materials.....	84
IV.2.1.2. Synthesis of hydrated DAPH^+Cl^-	84
IV.2.2. Physical measurements.....	84
IV.2.3. Crystal structure determination and refinement.....	85
IV.2.4. Hirshfeld surface analysis and energy framework analysis.....	85
IV.2.5. Bactericidal studies of the DAPH^+Cl^- compound.....	86
IV.2.5.1. Clinical microbial cultures and culture media.....	86

IV.2.5.2. Inculums and disc preparation.....	86
IV.2.5.3. Disc diffusion method (Kirby-Bauer method).....	86
IV.2.5.4. In vitro SARS-CoV-2 antiviral activity of the DAPH ⁺ Cl ⁻ compound.....	87
IV.2.5.4.1. Cytotoxicity assay against 1×10 ⁴ VeroE6 cells.....	87
IV.2.5.4.2. Immunofluorescence assay (IFA).....	87
IV.2.5.4.3. Molecular docking studies, ADME and molecular property Prediction.....	88
IV.2.5.4.4. Preparation of the ligand and receptors.....	88
IV.2.5.4.5. Creating a simulation box.....	89
IV.2.5.4.6. Validation of docking parameters.....	89
IV.2.5.4.7. Molecular dynamics (MD) simulation and molecular mechanics generalized born surface area (MM/GBSA) calculations.....	89
IV.3. Results and discussion.....	90
IV.3.1. Synthesis of DAPH ⁺ Cl ⁻	90
IV.3.2. Infrared spectral analysis of DAPH ⁺ Cl ⁻	91
IV.3.3. Electronic spectral analysis of DAPH ⁺ Cl ⁻	92
IV.3.4. ¹ H NMR spectrum analysis of DAPH ⁺ Cl ⁻	92
IV.3.5. Crystal structure, crystal engineering perspective and energy frameworks of DAPH ⁺ Cl ⁻	93
IV.3.6. Hirshfeld surface analysis of DAPH ⁺ Cl ⁻	99
IV.3.7. Bactericidal activity of DAPH ⁺ Cl ⁻	101
IV.3.8. In vitro SARS-COV-2 screening activity of DAPH ⁺ Cl ⁻	103
IV.3.8.1. Cytotoxicity of the DAPH ⁺ Cl ⁻	103
IV.3.8.2. Antiviral efficacy of DAPH ⁺ Cl ⁻ and remdesivir following immunofluorescence assay.....	105
IV.3.8.3. Molecular docking studies.....	105
IV.3.8.4. MD simulation and MMGBSA calculations.....	109
IV.4. Conclusion.....	117
References.....	119–122
Chapter V: A Direct Metal-free Synthetic Approaches for the Efficient Production of Priviledged Benzimidazoles in water medium under Aerobic Condition.....	123–168
V.1. Introduction.....	123
V.2. Experimental section.....	126
V.2.1. General procedure for the the synthesis of benzimidazole products.....	126

V.3. Experimental setup.....	127
V.3.1. Required apparatus and accessories.....	127
V.3.2. Reaction setup.....	128
V.4. Results and discussion.....	129
V.4.1. Optimization of the reaction.....	129
V.4.2. Substrate scopes.....	132
V.4.3. Industrial applicability of the methodology.....	135
V.4.4. Control experiments.....	136
V.4.5. Mechanistic pathway.....	138
V.5. Conclusion.....	141
V.6. Analytical data of the isolated benzimidazoles.....	142
V.7. ¹ H and ¹⁹ F spectra of the isolated benzimidazoles.....	150
V.8. Selected ¹³ C spectra of the isolated benzimidazoles.....	163
References.....	166–168
Chapter VI: Supramolecular Encapsulation of Nanocrystalline Schiff bases into β-cyclodextrin for Multifold Enrichment of Bio-potency.....	169–220
VI.1. Introduction.....	169
VI.2. Experimental section.....	170
VI.2.1 Chemicals, solvents and starting materials.....	170
VI.2.2 Preparation of nanocrystalline Schiff bases (H ₂ L ¹ and H ₂ L ²).....	171
VI.2.3 Preparation of the inclusion complexes of the Schiff bases with β-CD.....	171
VI.2.4 Physical Measurements.....	172
VI.2.5. Crystal structure determination and refinement.....	172
VI.2.6. Physicochemical characterization of the nanocrystalline materials.....	173
VI.2.7. Antitumor activity of the Schiff bases and their inclusion complexes.....	173
VI.2.7.1. Cell culture.....	173
VI.2.7.2. Cell viability via MTT assay and Haemolysis assay.....	173
VI.2.7.3. Cell cycle assay.....	174
VI.2.7.4. Apoptosis assay.....	174
VI.3. Results and discussion.....	175
VI.3.1. Synthesis of the Schiff bases and their β-CD complexes.....	175
VI.3.2. Synthesis of the β-CD inclusion complexes.....	175
VI.3.3. Electronic spectral analysis.....	175
VI.3.3.1. Infrared spectral analysis of Schiff bases and inclusion complexes.....	175

VI.3.3.2. ¹ H NMR spectral analysis of the Schiff bases and their inclusion Complexes.....	178
VI.3.3.3. Solution phase properties and hydrolytic stabilities.....	186
VI.3.4. Description of the crystal structures and supramolecular interactions of the Schiff bases.....	193
VI.3.5. Structural and morphological characteristics of H ₂ L ¹ and H ₂ L ² and their inclusion complexes.....	200
VI.3.6. Cytotoxicity studies.....	207
VI.3.6.1. Dose and time-dependent cytotoxicity against MCF-7 and MDA-MB-231 cells.....	207
VI.3.6.2 Cytotoxic effect of the inclusion complexes on normal human PBMC and RBCs.....	210
VI.3.6.3 Effect of the inclusion complexes on cell cycle arrest MCF-7 cell to sub-G1 stage.....	211
VI.3.7. Apoptotic cell death in MCF-7 cells induced by H ₂ L ¹ -β-CD and H ₂ L ² -β-CD complexes.....	212
VI.4. Conclusion.....	214
References.....	216–220
Chapter VII: Summary and future scope.....	221
APPENDIX.....	222
BIBLIOGRAPHY.....	225–246
INDEX.....	247–252